These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 23703789

  • 1. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R.
    Hepatology; 2013 Nov; 58(5):1655-66. PubMed ID: 23703789
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B.
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [Abstract] [Full Text] [Related]

  • 3. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
    Vouche M, Salem R, Lewandowski RJ, Miller FH.
    Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
    [Abstract] [Full Text] [Related]

  • 4. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 5. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [Abstract] [Full Text] [Related]

  • 6. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 7. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
    Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR.
    Eur Radiol; 2015 Feb; 25(2):380-90. PubMed ID: 25226843
    [Abstract] [Full Text] [Related]

  • 8. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
    Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R.
    J Hepatol; 2014 Aug; 61(2):309-17. PubMed ID: 24681342
    [Abstract] [Full Text] [Related]

  • 10. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 11. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014 Apr; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N, Camacho JC, Xing M, Qiu D, Kitajima H, Mittal PK, Kim HS.
    Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
    [Abstract] [Full Text] [Related]

  • 15. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
    Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V.
    Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
    [Abstract] [Full Text] [Related]

  • 16. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group.
    Trials; 2014 Dec 03; 15():474. PubMed ID: 25472660
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.